

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – April 10, 2019 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. March 13, 2019 DUR Minutes – Vote

B. March 13, 2019 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Long-Acting Beta₂-Agonist Utilization: Pediatric Members – See Appendix B

A. Medication Coverage Activity for March 2019

B. Pharmacy Helpdesk Activity for March 2019

C. Long-Acting Beta₂-Agonist Utilization: Pediatric Members

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Takhzyro™ (Lanadelumab-flyo) and to Update the Prior Authorization Criteria for Cinryze® (C1 Esterase Inhibitor), Haegarda® (C1 Esterase Inhibitor), and Kalbitor® (Ecallantide) – See Appendix C

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Adcetris® (Brentuximab Vedotin), Beleodaq® (Belinostat), Calquence® (Acalabrutinib), Folutyn® (Pralatrexate), Istodax® (Romidepsin), Poteligeo® (Mogamulizumab-kpkc), Truxima® (Rituximab-abbs), Zevalin® (Ibritumomab Tiuxetan), and Zolinza® (Vorinostat) – See Appendix D

A. Introduction

B. Market News and Updates

C. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Copiktra™ (Duvelisib) – See Appendix E

A. Introduction

B. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Lutathera® (Lutetium Lu 177 Dotatate) and Vitrakvi® (Larotrectinib) – See Appendix F

A. Introduction

B. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

9. Annual Review of Lung Cancer Medications and 30-Day Notice to Prior Authorize Lorbrena[®] (Lorlatinib), Mvasi[®] (Bevacizumab-awwb), and Vizimpro[®] (Dacomitinib) – See Appendix G

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Lung Cancer Medications
- D. Prior Authorization of Lung Cancer Medications
- E. Market News and Updates
- F. Product Summaries
- G. Recommendations
- H. Utilization Details of Lung Cancer Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

10. Annual Review of the SoonerCare Pharmacy Benefit – See Appendix H

- A. Summary
- B. Medicaid Drug Rebate Program
- C. Alternative Payment Models
- D. Drug Approval Trends
- E. Traditional Versus Specialty Pharmacy Products
- F. Top 10 Therapeutic Classes by Reimbursement
- G. Top 10 Medications by Reimbursement
- H. Cost Per Claim
- I. Conclusion
- J. Top 100 Reimbursed Drugs by Fiscal Year
- K. Top 50 Medications by Total Number of Claims
- L. Top 10 Traditional and Specialty Therapeutic Categories by Fiscal Year

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

11. Annual Review of Granulocyte Colony-Stimulating Factors (G-CSFs) and 30-Day Notice to Prior Authorize Fulphila[®] (Pegfilgrastim-jmdb), Nivestym[™] (Filgrastim-aafi), and Udenyca[™] (Pegfilgrastim-cbqv) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of G-CSFs
- C. Prior Authorization of G-CSFs
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of G-CSFs

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

12. Annual Review of Anti-Diabetic Medications – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Diabetic Medications
- C. Prior Authorization of Anti-Diabetic Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Non-Insulin Anti-Diabetic Medications
- G. Utilization Details of Insulin Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Cablivi[®] (Caplacizumab-yhdp) – See Appendix K

- A. Introduction
- B. Cablivi[®] (Caplacizumab-yhdp) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

14. 30-Day Notice to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase)

– See Appendix L

- A. Introduction
- B. Aldurazyme® (Laronidase) Product Summary
- C. Naglazyme® (Galsulfase) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

15. Annual Review of Antihypertensive Medications and 30-Day Notice to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kaspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Antihypertensive Medications
- C. Prior Authorization of Antihypertensive Medications
- D. Market News and Updates
- E. Consensi® (Amlodipine/Celecoxib Tablets) Product Summary
- F. Kaspargo™ Sprinkle (Metoprolol Succinate ER Capsules) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Antihypertensive Medications

Non-Presentation: Questions Only:

16. Industry News and Updates – See Appendix N

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

18. Future Business* (Upcoming Product and Class Reviews)

No live meeting scheduled in May 2019. May 2019 will be a packet only meeting.

- A. Bowel Preparation Medications
- B. H.P. Acthar® Gel (Repository Corticotropin Injection)
- C. Ophthalmic Anti-Inflammatories
- D. Testosterone Medications

**Future business subject to change.*

19. Adjournment